Physician profile
Daniel T Garber
NPI 1801997259
$6,482.62
in general payments reported to CMS, 2019-2025
9 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.04 · 2022: $125 · 2023: $118 · 2024: $5,942 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,988 · Food and Beverage: $1,123 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,987.79 |
| Food and Beverage | $1,122.82 |
| Education | $213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,937.80 | 2024 | |
| Eisai INC. | $1,988.62 | 2024 | |
| Jazz Pharmaceuticals INC. | $307.04 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $139.20 | 2022-2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $41.25 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $36.79 | 2023 | Inspire |
| Itamar Medical INC | $31.92 | 2025 | Watchpatone |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.